Back to top
more

Veeva Systems (VEEV)

(Delayed Data from NYSE)

$282.13 USD

282.13
846,410

+2.37 (0.85%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $282.35 +0.22 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 244)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

IBM to Reportedly Buy T-Systems' Mainframe Business Unit

by Zacks Equity Research

IBM (IBM) is reportedly buying mainframe service business of T-Systems amid cash crunch to capitalize on the growth prospects in the domain.

Zacks Equity Research

Cerner & Christiana Care Unite to Offer Bariatric Services

by Zacks Equity Research

Cerner (CERN) likely to gain from increased obesity rates in the United States.

Zacks Equity Research

Here's Why You Should Invest in Illumina (ILMN) Stock Now

by Zacks Equity Research

Illumina's (ILMN) product launches continue to contribute to the top line. The company's recent broadening of genotyping sequencing line buoys optimism.

Zacks Equity Research

Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio

by Zacks Equity Research

The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.

Zacks Equity Research

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining strength from the In Vitro Diagnostics (IVD) unit. The segment is a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray.

Zacks Equity Research

Here's Why You Should Invest in Veeva Systems (VEEV) Now

by Zacks Equity Research

Veeva Systems' (VEEV) focus on cloud-based systems like Veeva Vault makes it a solid pick.

Zacks Equity Research

Hill-Rom-Microsoft Tie-Up to Widen Digital Solutions Suite

by Zacks Equity Research

Hill-Rom (HRC) progresses with efforts to gain traction in the digital health space.

Zacks Equity Research

Masimo's (MASI) Preliminary Results for 2018 Cheer Investors

by Zacks Equity Research

Masimo (MASI) issues guidance for 2019. It anticipates witnessing strong contribution from its core product revenue segment.

Zacks Equity Research

Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results

by Zacks Equity Research

Intuitive Surgical (ISRG) is likely to gain from solid da Vinci contributions in fourth-quarter 2018.

Zacks Equity Research

Allscripts (MDRX) Collaborates With Microsoft, Shares Up

by Zacks Equity Research

Allscripts' (MDRX) Veradigm unit signs a memorandum of understanding with Microsoft to develop an integrated research model.

Zacks Equity Research

Intel, Warner Bros Alliance Ups the Ante in Self Driving Space

by Zacks Equity Research

Intel (INTC) demonstrated an immersive in-car entertainment experience at CES 2019 with Warner Bros, raising the bar in ADAS domain.

Zacks Equity Research

Has Veeva Systems (VEEV) Outpaced Other Computer and Technology Stocks This Year?

by Zacks Equity Research

Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?

Zacks Equity Research

The Meet Group Posts Preliminary Results, Raises Top-Line View

by Zacks Equity Research

The Meet Group (MEET) raises fourth-quarter and 2018 revenue estimates in its preliminary results.

Zacks Equity Research

Integra (IART) Rises 5% on Robust Preliminary Q4 Results

by Zacks Equity Research

Integra's (IART) total Q4 revenues are likely to be at the upper end of its prior guided range.

Zacks Equity Research

Akamai to Buy Janrain to Enhance Intelligent Edge Platform

by Zacks Equity Research

Akamai (AKAM) recently entered into an agreement to acquire Janrain in a bid to enhance its security solution portfolio and strengthen Intelligent Edge platform.

Zacks Equity Research

Boston Scientific Gains on Impressive Preliminary Q4 Results

by Zacks Equity Research

Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.

Zacks Equity Research

ResMed Announces Complete Mobi Launch in US Markets for COPD

by Zacks Equity Research

ResMed (RMD) progresses with efforts to boost Respiratory Care suite.

Zacks Equity Research

Luminex's (LMNX) Preliminary Q4 Results Cheer Investors

by Zacks Equity Research

Luminex (LMNX) likely to gain from strong segmental contributions in Q4.

Zacks Equity Research

Here's Why You Should Hold Varian Medical (VAR) Stock Now

by Zacks Equity Research

Exclusion of Varian Medical's (VAR) flagship Halcyon from Section 301 tariffs lends it a competitive edge in the MedTech space.

Zacks Equity Research

Veeva Systems (VEEV) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Veeva Systems (VEEV) closed at $94.78 in the latest trading session, marking a +0.73% move from the prior day.

Zacks Equity Research

QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales

by Zacks Equity Research

QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.

Zacks Equity Research

Hologic Stock Rides on Impressive Preliminary Q1 Result

by Zacks Equity Research

Hologic's (HOLX) strong top line is primarily expected on the back of balanced growth across a majority of the company's segments in Q1.

Zacks Equity Research

ResMed Closes Propeller Health Buyout, Boosts COPD Suite

by Zacks Equity Research

ResMed (RMD) expects to boost the Respiratory Care suite with the recently-completed Propeller Health buyout.

Zacks Equity Research

Abiomed's (ABMD) Preliminary Q3 Results Cheer Investors

by Zacks Equity Research

Abiomed (ABMD) raises its fiscal 2019 guidance. The company also expects to see strong contribution from its core Impella product line.

Zacks Equity Research

Baxter's PD Solution to Treat Patients, Prospects Bright

by Zacks Equity Research

Baxter's (BAX) kidney care portfolio likely to favor the company as kidney care demand shoots up in the United States.